Vivos Therapeutics, Inc.
VVOS
$0.80
$0.022.26%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -43.62% | 77.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -43.62% | 77.57% | |||
| Cost of Revenue | -70.63% | 66.43% | |||
| Gross Profit | -24.10% | 86.59% | |||
| SG&A Expenses | 7.74% | 24.26% | |||
| Depreciation & Amortization | 15.10% | 25.49% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.38% | 32.61% | |||
| Operating Income | -34.81% | 2.69% | |||
| Income Before Tax | -28.78% | -7.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.78% | -7.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -27.67% | -7.72% | |||
| EBIT | -34.81% | 2.69% | |||
| EBITDA | -36.55% | 4.58% | |||
| EPS Basic | -12.67% | 10.73% | |||
| Normalized Basic EPS | -12.09% | 10.73% | |||
| EPS Diluted | -12.67% | 10.73% | |||
| Normalized Diluted EPS | -12.09% | 10.73% | |||
| Average Basic Shares Outstanding | 13.31% | 20.65% | |||
| Average Diluted Shares Outstanding | 13.31% | 20.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||